Loading...
XNAS
ENTO
Market cap1mUSD
Jun 16, Last price  
0.50USD
1D
2.00%
1Q
-9.06%
IPO
-83.22%
Name

First Wave BioPharma Inc

Chart & Performance

D1W1MN
XNAS:ENTO chart
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
114.82%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-4.74%
-5,930,236-14,591,662-11,096,383-13,533,617-15,611,625-38,723,510-59,078,185-16,581,218-15,794,983
CFO
-9m
L-25.53%
00-4,510,778-4,534,859-7,184,638-10,869,320-14,033,502-11,221,538-32,288,218-22,344,079-12,377,852-9,217,823

Profile

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
IPO date
Oct 11, 2016
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
15,800
12,784
Unusual Expense (Income)
NOPBT
(15,800)
(12,784)
NOPBT Margin
Operating Taxes
1,952
Tax Rate
NOPAT
(15,800)
(14,736)
Net income
(15,795)
-4.74%
(16,581)
-71.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,226
15,830
23,296
BB yield
Debt
Debt current
82
680
670
Long-term debt
200
361
494
Deferred revenue
Other long-term liabilities
Net debt
118
(2,692)
(221)
Cash flow
Cash from operating activities
(9,218)
(12,378)
(22,344)
CAPEX
(500)
Cash from investing activities
88
(500)
Cash from financing activities
5,581
15,227
15,740
FCF
(55,767)
(15,471)
1,176,241,553
Balance
Cash
163
3,712
1,363
Long term investments
22
22
Excess cash
163
3,733
1,384
Stockholders' equity
(140,706)
(184,329)
(168,534)
Invested Capital
198,651
188,758
172,159
ROIC
ROCE
EV
Common stock shares outstanding
336
36
Price
Market cap
EV
EBITDA
49
(15,771)
(12,755)
EV/EBITDA
Interest
22
16
Interest/NOPBT